10:24 AM EDT, 08/07/2025 (MT Newswires) -- CorMedix ( CRMD ) shares fell by nearly 13% early Thursday after the company said it agreed to acquire Melinta Therapeutics for about $300 million in cash and stock.

Under the terms, CorMedix ( CRMD ) will pay $260 million in cash and $40 million in shares, with Melinta selling shareholders also eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of Minocin and Rezzayo, CorMedix ( CRMD ) said.

The transaction is expected to be accretive to earnings per share in the near term with double-digit accretion expected in 2026, CorMedix ( CRMD ) said, adding that annual run-rate cost savings are expected to be about $35 million to $45 million.

The deal is likely to close as early as Sept. 1, CorMedix ( CRMD ) said.

Price: 10.22, Change: -1.73, Percent Change: -14.48